Planning for pre‐exposure prophylaxis to prevent HIV transmission: challenges and opportunities

Kim, Susan C.; Becker, Stephen; Dieffenbach, Carl W.; Hanewall, Blair S; Hankins, Catherine; Lo, Ying-Ru; Mellors, John W.; O’Reilly, Kevin; Paxton, Lynn A.; Roffenbender, Jason S.; Warren, Mitchell; Piot, Peter; Dybul, Mark

doi:10.1186/1758-2652-13-24

Cited by 42 publications

(38 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…RV144: Been reported encouraging results in September 2009 with the effectiveness of the vaccine is estimated at 31.2% [61][62][63]. This study, known as RV144, conducted by the US military research program in collaboration with several Thai institutions in more than 16,000 Thai associate with any particular danger in advance of HIV [64][65][66].…”

Section: Step Studymentioning

confidence: 99%

Efficacy Trials and Progress of HIV Vaccines

Asif¹,

Irshad²

2017

J Cell Sci Ther

View full text Add to dashboard Cite

Discovery of HIV as causative agent of AIDS let to the belief that a vaccine for AIDS will be available shortly but was not that easy, and it took more than 30 years of hard laboratory and clinical work toward HIV vaccine development. Efficacy trials of RV144 and their results revealed that HIV vaccine is accomplishable. Clinical trials for developing bNAbs has monoclonal antibodies and to increase its half-life are also underway to achieve a proper HIV vaccine. In this review article, we see that how these efficacy trials are highlighting HIV vaccine concepts in clinical development. Therapeutic vaccines are proving to be a functional cure toward HIV treatment and progress is ongoing in such HIV vaccine development which will attack HIV before it fuses with cell and cause infection thus preventing AIDS. So, in near future it will be possible to cure HIV and bring an end to this epidemic.

show abstract

Section: Step Studymentioning

confidence: 99%

Efficacy Trials and Progress of HIV Vaccines

Asif¹,

Irshad²

2017

J Cell Sci Ther

View full text Add to dashboard Cite

show abstract

“…Since then there have been major advances in both, the treatment and prevention of HIV/ AIDS. Pre-exposure prophylaxis [7][8][9][10] and the use of ART for prevention have positively impacted the available prevention options. In fact, current evidence strongly supports early initiation of ART, as it not only improves the health of infected individuals but also reduces the risk of HIV transmission [11][12][13].…”

Section: The Need For An Anti-hiv Vaccinementioning

confidence: 99%

HIV Vaccine Development: Current Scenario and Future Prospects

Ajbani¹

2016

J AIDS Clin Res

View full text Add to dashboard Cite

The search for a preventive vaccine that can halt the global pandemic is the ultimate goal of HIV research. Development of a vaccine against HIV-1 has been plagued by many insurmountable challenges. Different vaccine concepts have been tested to overcome these challenges. Experimental vaccines that showed promise in preclinical studies were advanced into clinical trials. Yet, human trials proved to be a huge disappointment until the results of the RV144 trial in Thailand. This trial not only provided the first evidence of a modest efficacy, but also valuable insights on the possible immunologic correlates of vaccine protection. Currently, the HIV vaccine research landscape has been rejuvenated by two major developments. On one hand, there has been a resurgence of interest in T cell-based vaccines with the promising results obtained using a recombinant cytomegalovirus vector vaccine. On the other hand, the discovery of more than a hundred broadly neutralizing antibodies from cohorts of HIV-infected individuals has led to the development of antibody-based preventive vaccines. Innovations in the design of vaccines, vaccination strategies and clinical trial programs will be necessary to accelerate the search for a prophylactic HIV vaccine. This article reviews the current status of HIV vaccine research and provides a roadmap to future efforts in vaccine development.

show abstract

“…57 Broader stakeholder engagement started in 2005, and only in 2008 WHO, UNAIDS, the Forum for Collaborative HIV Research, and the Global Advocacy of HIV Prevention (AVAC) engaged in preparing for potential PrEP implementation with the support of the DAIDS, US NIH, and the BMGF. [58][59][60] Debate about the potential implementation of PrEP in resource-limited settings started. [61][62][63][64] Early modeling studies postulated that PrEP could potentially have a positive impact as part of combination prevention.…”

Section: Pre-exposure Prophylaxismentioning

confidence: 99%

Stakeholder Engagement in HIV Cure Research: Lessons Learned from Other HIV Interventions and the Way Forward

Chu

Ananworanich

et al. 2015

AIDS Patient Care and STDs

View full text Add to dashboard Cite

Clinical and basic science advances have raised considerable hope for achieving an HIV cure by accelerating research. This research is dominated primarily by issues about the nature and design of current and future clinical trials. Stakeholder engagement for HIV cure remains in its early stages. Our analysis examines timing and mechanisms of historical stakeholder engagement in other HIV research areas for HIV-uninfected individuals [vaccine development and pre-exposure prophylaxis (PrEP)], and HIV-infected individuals (treatment as prevention, prevention of mother-to-child transmission, and treatment of acute HIV infection) and articulate a plan for HIV cure stakeholder engagement. The experience from HIV vaccine development shows that early engagement of stakeholders helped manage expectations, mitigating the failure of several vaccine trials, while paving the way for subsequent trials. The relatively late engagement of HIV stakeholders in PrEP research may partly explain some of the implementation challenges. The treatment-related stakeholder engagement was strong and community-led from the onset and helped translation from research to implementation. We outline five steps to initiate and sustain stakeholder engagement in HIV cure research and conclude that stakeholder engagement represents a key investment in which stakeholders mutually agree to share knowledge, benefits, and risk of failure. Effective stakeholder engagement prevents misconceptions. As HIV cure research advances from early trials involving subjects with generally favorable prognosis to studies involving greater risk and uncertainty, success may depend on early and deliberate engagement of stakeholders.

show abstract

Planning for pre‐exposure prophylaxis to prevent HIV transmission: challenges and opportunities

Cited by 42 publications

References 15 publications

Efficacy Trials and Progress of HIV Vaccines

Efficacy Trials and Progress of HIV Vaccines

HIV Vaccine Development: Current Scenario and Future Prospects

Stakeholder Engagement in HIV Cure Research: Lessons Learned from Other HIV Interventions and the Way Forward

Contact Info

Product

Resources

About